Anti-GITR antibodies - Bristol-Myers Squibb

Drug Profile

Anti-GITR antibodies - Bristol-Myers Squibb

Alternative Names: Anti-AITR antibody; Anti-CD357 antibody; Anti-GITR-D antibody; Anti-TNFRSF18 antibody

Latest Information Update: 19 Mar 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 26 Feb 2016 Phase-I clinical trials in Cancer in USA (unspecified route) (Bristol-Myers Squibb website, March 2016)
  • 05 Jan 2016 Bristol-Myers Squibb has patent protection for Anti-GITR antibodies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top